All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. View funders.
Bookmark this article
At the 24th Congress of the European Hematology Association (EHA), Marie José Kersten from Amsterdam UMC, Amsterdam, NL, talks about access and implementation of chimeric antigen receptor (CAR) T treatment in lymphomas.
Professor Kersten stated in the coming years, we need to increase access to these therapies in Europe and overcome the challenges in implementation. These include delivering the therapy to the patient and managing the side effects which will inevitably lead to a busy time for hematologists in the field.
Professor Kersten stated that the EHA were trying to make delivering CAR T easier for centers - though training and education are the main priority. This is true for both treatment centers and referral centers as it is Professor Kersten's opinion that timely referral and appropriate patient selection is crucial.
Access and implementation of CAR T treatment in lymphoma
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox